公开(公告)号：US11359197B2

公开(公告)日：2022-06-14

申请号：US17165841

申请日：2021-02-02

申请人： Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

发明人： Richard E. Olson ,  Angela M. Cacace ,  Jere E. Meredith, Jr. ,  Nino Devidze ,  James K. Loy ,  Carl J. Baldick ,  Annapurna Pendri ,  Ivar M. McDonald ,  Peter Hagedorn ,  Marianne Lerbech Jensen

IPC分类号： C12N15/113

摘要： The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

公开(公告)号：US20230193260A1

公开(公告)日：2023-06-22

申请号：US17815493

申请日：2022-07-27

申请人： Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

发明人： Richard E. OLSON ,  Angela M. Cacace ,  Jere E. Meredith, JR. ,  Nino Devidze ,  James K. Loy ,  Carl J. Baldick ,  Annapurna Pendri ,  Ivar M. McDonald ,  Peter Hagedorn ,  Marianne Lerbech Jensen

IPC分类号： C12N15/113

CPC分类号： C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/351 ,  C12N2310/3231

摘要： The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

公开(公告)号：US11447775B2

公开(公告)日：2022-09-20

申请号：US16961624

申请日：2019-01-11

申请人： Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

发明人： Richard E. Olson ,  Angela M. Cacace ,  Jere E. Meredith, Jr. ,  Nino Devidze ,  James K. Loy ,  Carl J. Baldick ,  Annapurna Pendri ,  Ivar M. McDonald ,  Peter Hagedorn ,  Marianne Lerbech Jensen

IPC分类号： C07H21/04 ,  C12N15/113

摘要： The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

公开(公告)号：US11827695B2

公开(公告)日：2023-11-28

申请号：US17152051

申请日：2021-01-19

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Michael K. Ahlijanian ,  Jere Ernest Meredith, Jr. ,  Nino Devidze ,  John David Graef ,  Edward L. Halk

IPC分类号： C07K16/18 ,  A61K39/395 ,  A61P25/16 ,  A61P25/28

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61P25/16 ,  A61P25/28 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/92

摘要： Disclosed herein are anti-α-synuclein antibodies which preferentially bind to oligomeric α-synuclein over monomeric α-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.

公开(公告)号：US11142570B2

公开(公告)日：2021-10-12

申请号：US16486238

申请日：2018-02-16

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Michael K. Ahlijanian ,  Jere Ernest Meredith, Jr. ,  Nino Devidze ,  John David Graef ,  Edward L. Halk

IPC分类号： C07K16/18 ,  A61K39/395

摘要： Disclosed herein are anti-α-synuclein antibodies which preferentially bind to oligomeric α-synuclein over monomeric α-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.